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Preparative regimens
BEAM D-5 D-4 D-3 D-2 D-1
Etoposido 200-300 mgs/m2/day X X X X
BiCNU 300 mgs/m2/day X
Citarabine 300 mgs/m2/day X X X
Melfalan 140 mgs/m2/day X
CBV
Cyclosphaphamide 2.000 mgs/m2/day X X X
BiCNU 300 mgs/m2/day X
Etoposide 300 mgs/m2/day X X X
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compare responses and toxicities.
Results: The median age of the patients was 58 yrs (range:
39-72) in Group A and 58 yrs (range: 49-68) in Group B.
Group A had more female pts (56% vs 25%) and a decreased
baseline renal function (median creatinine clearance 76 vs
108 ml/min) compared to Group B. There was no signiﬁcant
difference in disease status pre-2nd ASCT between the 2
groups. Salvage therapywas given to 12 pts in group A and 16
pts in group B. The median time between 2 ASCTs were 29
(range: 3-67) months in group A vs 35.5 (range: 18-58)
months in group B. All patients received stem cells which
were collected and cryopreserved prior to the 1stASCT. At day
+100, seven patients from Group B had CR compared to 2
from group A (p¼.11) (Table 1). Patients who received BEAM
had higher incidence of febrile neutropenia (16 vs 10 pts) and
longer hospitalization (23 vs 15 days, p <.0001). Other
toxicities were not signiﬁcantly different between these
groups.
Conclusion: BEAM seems to be a viable and tolerable con-
ditioning regimen for 2ndASCT in MM pts. Further analyses
including PFS and OS are planned to better deﬁne the two
groups.143
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Small series have shown that it is possible perform autolo-
gous hematopoietic transplant in lymphoma patient without
cryopreservation. In most of them, CBV like or BEAM liker-
egimen were used, but with important modiﬁcations of the
intensity of dose delivered, or using different drugs . We
present our experience in a large group of lymphoma pa-
tients using non-cryopreserved stem cells after administra-
tion of BEAM or CBVwithout alteration of the total amount of
chemotherapy of these regimens.
The mobilization was done with ﬁlgrastin 5 mg/kg/BID for
ﬁve to six days, after that, one or two leukopheresis of 3 to 5
blood volume was done; the cells were stored at 4oC, 6 days
for ﬁrst leukopheresis, and 5 for the second one. The pre-
parative regimen began in the evening of the last pheresis,
this was the day e 5. All patients received ﬁlgrastim or
pegﬁlgrastim after the transplant82 ptes in whom were
collected at least 1.0 x 10(6) CD 34/kg (X: 2.5) were trans-
planted; 49 were men, median age was 36 Y (11-65), 42 had
Hodgkin disease and 40 had lymphoma, the totality of them
were in CR2 or beyond. 65 received BEAM and 17 CBV. The
median viability of the cells after 6 days of refrigeration
(trypan blue exclusion) was 82% (range 66-90). All patients
had fast and complete neutrophil engraftment; median time
to achieve 500/ul or more was 12 days (9-23), 79 were
evaluable for thrombopoiesis, 78 of them had a self- sus-
tained platelets count of 20.000 or more at a median of 17
days (range 9-50). There has not been secondary engraft-
ment failure.
The tolerance and efﬁcacy of the BEAM and CBV adminis-
tered in 5 days was good; the transplant related mortality
was 3.6% and the Kaplan Meir estimate for OS at 36 months
was 65% and 58% for patients with Hodgkin and lymphoma
respectively.We conclude; the use of non-cryopreserved stem cell for
supporting autologous transplant after a BEAM or CBV con-
ditioning is feasible, safe, and produce a fast, complete and
sustained hematopoiesis. This simple procedure is a good
alternative for saving costs and it can expand the number
of lymphoma patients who would receive the beneﬁt of
tranplant.144
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Background: Standard initial therapy for a minority of
patients with systemic AL amyloidosis is risk-adapted
melphalan and stem cell transplant (SCT) with SC mobiliza-
tion often accomplished with high dose G-CSF (16mg/kg/d).
Based on the phase III experience in MM, we investigated the
combination of G-CSF and Plerixafor for stem cell mobiliza-
tion in AL. We report an update of our experience with this
mobilization approach.
Methods: Patients were diagnosed by standard criteria with
tissue biopsies showing amyloidosis. They were mobilized
and collected between 4/16/12 and 9/11/13 with G-CSF 10mg/
kg/d subcutaneously (SC) for 5 days (and continued through
collection) and Plerixafor, adjusted for renal function, start-
ing on day 4 until collection was completed.
Results: We report on 12 patients whose median age at
mobilization was 58 yrs (range 46-72), 58% of whom were
men. Median number of organs involved was 2 (range 1-4),
most frequently the kidneys (n¼9) and the heart (n¼8).
Median time from diagnosis to mobilization was 7.5 mths
(range 2-123). 9 patients had prior bortezomib-based ther-
apy with a median of 3 cycles (range 0-6). One had received a
SCT 10 years prior and relapsed, and one was 1 yr s/p
orthotopic heart transplant. 5 patients had a creatinine of 
1.5 mg/dL including 2 on hemodialysis. The target CD34+ cell
dose was 10 x 106 CD34/kg for all but one patient due to the
history of prior SCT. The median number of collections was 2
(range 2-3). On day one, a median of 3.6 x106 CD34/kg (0.4-
13.8x106) was collected and on day two, 6.4 x106 (2.7-
19x106). The median total CD34+ cells collected per kg was
13.8x106 (5-18x106). No signiﬁcant toxicities were observed
with Plerixafor. 2 patients had grade 1 bleeding from the
catheter site during apheresis and one had dyspnea with
suspected ﬂuid overload which responded to furosemide.
All patients went on to receive high dose chemotherapy
with melphalan followed by autologous SCT. The median
stem cell dose infused was 7.7x 106 CD34/kg and median
days to ANC > 500 was 11 (10-22), to platelets > 20K
untransfused was 22 (15-44) and to lymphocytes > 500/ml
was 14.5 (11-25). One patient who had VOD and persistent
